CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 171 enrolled
Drug / intervention
avelumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05650164
NCT05650164N/ACompleted
CompareCT.gov

A Multicenter, NI, Retrospective, Observational Study Evaluating Real-World Treatment Outcomes in Japanese Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Avelumab Plus Axitinib as First-line Therapy: J-DART2

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany·observational·Posted Dec 14, 2022·Updated Mar 28, 2025

In Brief

An observational study evaluating avelumab and axitinib for Renal Cell Carcinoma. Completed, enrolled 171 participants across 19 sites.

Detailed Summary

This study is a multicenter, non-interventional, retrospective, medical chart review of participants with metastatic renal cell cancer(mRCC) treated with avelumab plus axitinib as a first-line therapy in Japan between 20 December 2019 and 17 October 2022. All decisions regarding clinical management and treatment of the participating patients were made by the investigator as part of standard care in real-world clinical setting and were not contingent upon the patient's participation in the study. Data will be collected if available per study site.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Cell Carcinoma
CountriesJapan
Collaborators--

Timeline

N/ACompletedFinished
2023202420252026
First PostedDec 14, 2022
Enrollment StartJan 25, 2023
Primary CompletionOct 13, 2023
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 3.6 years ago

Interventions

avelumabdrug

as provided in real world practice

axitinibdrug

as provided in real world practice